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Objective: Evidence regarding the influence of cardiovascular risk factors, comorbidities, and patient characteristics on the
growth of small abdominal aortic aneurysms (AAA) is limited. We assessed, in an observational cohort study, rupture
rates, risks of mortality, and the effects of cardiovascular risk factors and patient demographics on growth rates of small
AAAs.
Methods: Between September 1996 and January 2005, 5057 patients with manifest arterial vascular disease or cardiovas-
cular risk factors were included in the Second Manifestation of ARTerial disease (SMART) study. Measurements of the
abdominal aortic diameter were performed in all patients. All patients with an initial AAA diameter between 30 and 55
mm were selected for this study. All AAA measurements during follow-up until August 2007 were collected. Multivariate
regression analysis was performed to calculate the effects of demographic patient characteristics, initial AAA diameter,
and cardiovascular risk factors on AAA growth.
Results: Included were 230 patients, with a mean age of 66 years and 90% were male. Seven AAA ruptures (six fatal)
occurred in 755 patient years of follow-up (rupture rate 0.9% per patient-year). In 147 patients, AAA measurements were
performed for a period of more than 6 months. The median follow-up time was 3.3 years (mean 4.0, range 0.5 to 11.1
years, standard deviation (SD) 2.5). Mean AAA diameter was 38.8 mm (SD 6.8) and mean expansion rate 2.5 mm/y.
Patients using lipid-lowering drugs had a 1.2 mm/y (95% confidence interval [CI] 2.34 to0.060 mm/y) lower AAA
growth rate compared to nonusers of these drugs. Initial AAA diameter was associated with a 0.09 mm/y (95% CI 0.01
to 0.18 mm/y) higher growth rate per millimetre increase of the diameter. No other factors, including blood lipid values,
were independently associated with AAA growth.
Conclusions: Lipid-lowering drug treatment and initial AAA diameter appear to be independently associated with lower
AAA growth rates. The risk of rupture of these small abdominal aortic aneurysms was low, which pleads for watchful
waiting. (J Vasc Surg 2008;47:1127-33.)Abdominal aortic aneurysms (AAA) are generally diag-
nosed when the maximal aortic diameter reaches 30 mm or
more. Evidence on factors that determine an AAA expan-
sion rate is limited. Recently, results of animal studies
suggested an association between statin use and suppres-
sion of the development of aortic aneurysms.1 Few authors
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doi:10.1016/j.jvs.2008.01.041have reported the effect of statins on human aortic aneu-
rysms in vivo. Sukhija showed in a nonrandomized obser-
vational cohort study that statins were significantly associ-
ated with attenuation of AAA growth.2 Schouten et al3
showed a similar effect of statins on AAA growth and
adjusted the effect for several other factors. Until present
and as far as we know, no more data are available on the
impact of statins on human abdominal aneurysm expansion
rates.
Good evidence exists for the association between the
initial AAA diameter and AAA growth rates.3-11 However,
data on the predictive value of smoking,4, 9,12-15 hyperten-
sion,4,12,16-18 age,3-4,9,15,17,19 gender,3-5,19 B-blockers us-
age,8,10,20-22 and diabetes mellitus3-4,12,15 are inconsis-
tent. Factors that are consistently not associated with AAA
growth rates include chronic obstructive pulmonary dis-
ease,3,12,23 lipids,4,12,18 and body weight.4,8,13,17 Other
factors and their association with AAA growth rates are
reported to a lesser extent and include alcohol abuse,
genetics, Chlamydia pneumonia, usage of NSAIDs,
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tic drugs, past medical history of peripheral vascular
disease, cardiac disease and other cardiovascular diseases,
organ transplantation, body length, several laboratory
values, and the extend of thrombus in the aneurysm sac.
Better insight into predictors of AAA expansion may lead
to future improvements in the efficiency of follow-up,
future therapies to slow AAA growth, and a better selec-
tion of patients for surgery to prevent AAA rupture.
The aim of this study is to estimate overall rupture
rates of small AAAs and to investigate a predefined set of
demographic characteristics and cardiovascular risk fac-
tors for association with abdominal aortic aneurysm
growth.
METHODS
Study population. The Second Manifestations of
ARTerial disease (SMART) study is a prospective cohort
study among patients aged 18 to 79 years, referred to the
University Medical Center Utrecht, The Netherlands, with
clinically manifest (symptomatic) atherosclerotic disease or
risk factors for atherosclerosis. Clinically manifest athero-
sclerotic diseases included internal carotid artery stenosis,
transient ischemic attack, peripheral arterial disease, minor
stroke, angina pectoris, myocardial infarction, renal artery
stenosis, and abdominal aortic aneurysm. Risk factors for
atherosclerosis included hyperlipidemia, diabetes mellitus,
hypertension, and renal insufficiency. The detailed study
design has been described previously.24 The main objec-
tives of the SMART study are to determine the prevalence
of concomitant arterial disease, and risk factors in patients
and to investigate the incidence of future cardiovascular
events and its predictors in these patients. The study was
approved by the ethics committee. Written informed con-
sent was obtained from all patients. For the current study,
we included the first consecutive 5057 participants who
were recruited in SMART between September 1996 and
January 2005.
Measurements. All patients underwent a standardized
vascular screening including a health questionnaire, labora-
tory assessment, and ultrasonography. Ultrasound scan-
ning of the abdomen was performed tomeasure the antero-
posterior juxtarenal diameter and the distal anteroposterior
diameter of the aorta and the length and volume of the
kidneys. All ultrasonographic measurements were taken in
the University Medical Center Utrecht by well-trained
registered vascular technologists in a certified vascular lab-
oratory. Ultrasonography of the abdomen was performed
with an ATL 3000 HDI (Advanced Technology Laborato-
ries, Bethel, Wash) equipped with a 4-MHz curved-array
transducer. No bowel preparation was performed before
the ultrasound measurement. If an AAA was detected dur-
ing the SMART study, this finding was reported to the
treating specialist and general practitioner with a treatment
suggestion. The following treatment policy was recom-
mended to the patient’s general practitioner if an AAA was
detected: indication for surgical repair if the diameter of the
AAA was 55 mm or larger; smaller aneurysms requiredfollow-up ultrasound examinations to determine the
growth rate, every 12 months was recommended for AAAs
with a diameter between 30 and 39 mm; and every 6
months for AAAs with a diameter of 40 to 55 mm. The
treatment policy was recommended. A final decision about
treatment was subsequently made by the treating specialists
and patients.
The following definitions were used in this study: cere-
bral vascular disease: a history of a stroke, transient ischemic
attack, or carotid artery surgery; diabetes: fasting plasma
glucose 126 mg/dl, nonfasting serum glucose 200
mg/dl, or use of oral antidiabetic drugs or insulin; hyper-
lipidemia: a total cholesterol 250 mg/dl, triglycerides
210 mg/dl or high-density lipoprotein (HDL)-cholesterol
40 mg/dl; renal failure was defined by plasma creatinine
1.35 mg/dl or microproteinuria 30 mg per 1 g of
creatinine; homocysteinemia: homocysteine in males 2.5
mg/l and in females 2.2 mg/l. Assessment of creatinine
clearance (Cockcroft) resulted in classification into “normal
(80.0 ml/min)” and “moderate or severe insufficiency
(80.0 ml/min).” Hypertension was analyzed for two
definitions: (1) hypertension 160/95 mm Hg: systolic
blood pressure 160 mm Hg, diastolic blood pressure
95 mm Hg or use of antihypertensive drugs; and (2)
hypertension 140/80 mm Hg: systolic blood pressure
140 mmHg, diastolic blood pressure80 mmHg or use
of antihypertensive drugs. Smoking was classified into “no
smoking history or past smoking” and “recently quitted or
current smoking.” Questionnaires were sent to the in-
cluded patients every 6 months, or information about their
health status was obtained from their general practitioners.
All patients that were examined for their AAA size more
than 12 months ago were invited for new ultrasound mea-
surement of the actual AAA diameter to minimize the
number of patients lost to follow-up. Outcome events that
were recorded included death, cause of death, AAA rup-
tures, AAA surgery, and other vascular diseases. Calculation
of the rupture rate was performed by dividing the total
number of ruptures by the total follow-up time of patients
at risk for AAA rupture. The follow-up time of patients at
risk for AAA rupture was defined by the total follow-up
time of all patients between the initial AAA diameter mea-
surements and subsequent surgical AAA repair, rupture,
death, or end of follow-up of the study.
All patients with AAAs with a maximal diameter be-
tween 30 and 55 mm who were examined by at least two
AAA diameter measurements and with at least 6 months of
follow-up were selected. The follow-up period for this
study ended in August 2007.
Data analysis. The change in maximum AAA diame-
ter was calculated with linear regression analysis. The re-
gression coefficient, using time as the independent variable
and diameter of AAA as the dependent variable, was used as
an estimation of the AAA expansion rate for each patient.3
Associations between demographic patient characteristics,
AAA diameters and cardiovascular risk factors, and AAA
growth rate were calculated with univariate linear regres-
sion analysis. Age, sex, initial AAA diameter, and variables
hs of f
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disease-specific category, were entered in a multivariate
regression model to calculate independent effects on AAA
growth rate. Cox regression analysis was used to model
age-adjusted survival time.
RESULTS
Patient characteristics. The total study population
consisted of 230 patients (90% men). Four patients were
lost to follow-up (1.7%). All other patients were followed
until death, AAA surgery, or till the most recent AAA
examination within 1 year before the end of follow-up of
this study.
From the total population, 79 AAAs (34%) were not
detected before the patient participated in the vascular
screening program. The baseline patient characteristics are
given in Table I. The mean age at first presentation was 66
years (range 45-79 years), and 90% were male. Consider-
able cardiovascular comorbidity was present, and 37% used
lipid-lowering drugs. Medical history investigation re-
vealed that 98% of the patients with lipid-lowering drug
treatment were using statins. Themeanmaximumdiameter
at first presentation of the AAA was 41  8.0 mm. The
mean maximum initial AAA diameter was not significantly
different between men and women (41.5 mm vs 39.0 mm,
respectively).
Ruptures. In 47% of the 230 patients, elective AAA
surgery was performed: in 62 (57%) conventional and in 46
(43%) endovascular repair. The AAA diameters of patients
Table I. Clinical baseline characteristics at first screening v
Males, (%)
Age in y (SD)
AAA diameter in mm (SD)
Medical history
Myocardial infarction (%)
Stroke (%)
Cardiac surgery (%)
Cardiac vascular disease (%)
Peripheral vascular disease (%)
Hypertension  160/95 mm Hg (%)
Hypertension  140/80 mm Hg (%)
Diabetes mellitus (%)
Weight in kg (SD)
Body length in cm (SD)
BMI in kg/m2 (SD)
Obesities, BMI  30 (%)
Ankle brachial index  0.9 (%)
Carotid artery stenosis  50% (%)
Carotid artery stenosis  70% (%)
Hyperlipidemia (%)
Lipid-lowering drug treatment (%)
Renal failure (%)
Hyperhomocysteinemia (%)
Smoking (%)
BMI, Body mass index; SD, standard deviation.
aPatients with 2 documented AAA diameter measurements and 6 montwho underwent elective AAA repair are shown in Fig 1. Themean AAA diameter was 54.4 5.7 mm before surgery. In
total, seven AAA ruptures occurred in 755.3 patient years
of follow-up time of patients at risk (before surgery) for
AAA rupture. This corresponds with a rupture rate of 0.9%
per patient-year. Table II shows characteristics of the seven
patients with AAA ruptures. The two smallest aneurysms
where 43 mm at the last measurement: one had an expan-
sion rate of only 1.9 mm/y, whereas the other was a female
patient with a growth rate of 5.2 mm/y. In three patients,
Total
 230)
Selection for study of AAA
expansion ratesa (N  147)
07 (90) 131 (89)
66 (7.6) 65 (7.7)
41 (8.0) 39 (6.8)
61 (27) 38 (26)
29 (13) 20 (14)
50 (22) 29 (20)
97 (42) 57 (39)
34 (15) 23 (16)
32 (57) 90 (61)
89 (82) 128 (87)
47 (20) 35 (24)
82 (14) 83 (14)
76 (7.8) 176 (7.9)
26 (3.6) 27 (3.7)
33 (14) 23 (16)
68 (30) 43 (29)
56 (24) 36 (24)
46 (20) 28 (19)
59 (69) 102 (69)
86 (37) 63 (43)
58 (25) 37 (25)
53 (23) 36 (24)
91 (40) 59 (40)
ollow-up.
Fig 1. Abdominal aortic aneurysms (AAA) sizes of patients who
underwent elective AAA surgery. The AAA diameters are shown of
patients who underwent elective AAA repair and the AAA diame-
ters were measured recently before surgery (6 months).isit
(N
2
1
1
1
1emergency repair was performed and one of those survived.
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dilatation of the iliac arteries was documented in one pa-
tient. No association between AAA expansion rate and
AAA rupture could be established (Cox regression analysis,
P .22).
Expansion rate. All patients who had been examined
by at least two AAA diameter measurements and with at
least 6 months of follow-up were selected for analysis of the
AAA expansion rates. Total follow-up time of the AAA
expansion rates was 599 patient-years. Patients who were
excluded (n  83) had not been examined by at least two
AAA diameter measurements or did not have 6 months of
follow-up. Efforts were made during the last year to obtain
recent AAA measurements of all patients. Four patients
were lost to follow-up. The AAAs of the other patients
could not be measured anymore because they already had a
history of AAA surgery (n  52), AAA rupture (n  1), or
death (n 26). Themedian period of AAA surveillance was
3.3 years (range 0.5 to 11.1 years).
The mean aneurysm expansion rate during follow-up
was 2.5 mm per year (SD 3.2). A wide variation was found
between individuals (SD 3.2, range 7.8 to 19 mm per
year). Univariate analysis revealed that lipid-lowering drug
use was associated with significant lower aneurysm growth
rates. The difference between nonusers and users was 1.21
mm per year (95% CI 0.19 to 2.24 mm per year, P  .02).
Low-density lipoprotein (LDL), HDL cholesterol, and
triglycerides did not significantly influence the AAA growth
rate. Other possible risk factors, such as smoking, hyperten-
sion, and hyperhomocysteinemia were also not significantly
associated with differences in AAA expansion rates. The
results of the univariate regression analysis are presented in
Table III.
Table IV shows the results of the multivariate linear
regression analysis. Lipid-lowering drug use and lower
initial AAA diameter were independently associated with
lower AAA growth rates. Lipid-lowering drug users had a
1.20 mm per year attenuation in AAA growth compared
Table II. Characteristics of the seven patients with AAA
ruptures
Ageb (y) Sex AAA diametera (mm)
AAA expansion
rate (mm/y)
1 78 Male 52 NA
2 71 Male 43 1.9
3 80 Female 43 5.2
4 74 Male 50 1.7
5 73 Male 50 5.3
6 72 Male 55c 3.4
7 70 Male 59 3.5
AAA, Abdominal aortic aneurysms; NA, Not available, only one ultrasound
measurement of the AAA diameter available.
aAAA diameter measured at last AAA examination before AAA rupture
occurred.
bAge at moment of AAA rupture.
cDilatation of the iliac arteries present too.with nonusers (95% CI .060 to 2.34 mm per year).Growth rates increased with 0.094 mm per year (95%
CI .009 to .178) with every mm increase in initial AAA
diameter. We did not find significant influences of other
factors on aneurysm growth rate.
Mortality. Cox regression was used for modeling sur-
vival time. Total follow-up time for mortality was 1147
patient-years. Fig 2 shows the overall survival plot of the
patients in our study (n 230). After adjustments for age
were made, no significant association between lipid-
lowering drug use and survival time was found (P value
.30). The causes of death of the patients are presented in
Table V.
DISCUSSION
Higher initial AAA diameter appears to be associated
with higher AAA expansion rates and lipid-lowering drug
use with lower expansion rates. The rupture rate of these
small abdominal aortic aneurysms was low: 0.9% per patient
per year.
Lipid-lowering treatment consisted of statins in virtu-
ally all patients (98%) in this cohort. The pathophysiology
of aortic aneurysm growth and rupture, and the mecha-
nisms of effects of statins on this are still not fully under-
stood. The association between LDL cholesterol and AAA
formation has been shown by Hobbs et al.25 They com-
pared males with AAAs with age-matched controls and
concluded that LDL cholesterol was significantly associated
with the formation of small AAAs. In our study, we found
no significant effects of LDL and HDL cholesterol on the
growth rate of AAAs, which may plead for so called pleio-
tropic effects of statins as an underlying mechanism of
decreasing AAA growth. Several experimental studies in
mice and rats have reported the effect of statins on AAA
growth rates. A Taiwanese study by Liu et al concluded that
pravastatin significantly reduced the area of aortic athero-
sclerotic lesions in ApoE-deficient mice.26 Steinmetz et al
demonstrated that simvastatin reduced AAA growth in
mice. This was associated with preservation of medial elas-
tin and vascular smooth muscle cells, a relative reduction in
aortic wall expression of matrix metalloproteinase
(MMP)-9, and a relative increase in expression of tissue
inhibitor of metalloproteinases (TIMP)-1.1 Another study
showed that simvastatin significantly suppressed experi-
mental aneurysm expansion and reduces protein levels of
MMP-9 and nuclear factor- in rats, and that several
mediators of inflammation, matrix remodeling, and oxida-
tive stress were downregulated by simvastatin treatment.27
A recent randomized placebo-controlled trial in only 21
patients elective for open AAA repair demonstrated that
simvastatin reduced levels of MMP-9 in the AAA wall by
40%.28 MMPs play probably a pivotal role in the develop-
ment and progression of AAAs, and the reduction of levels
and activity of these enzymes may explain the mechanism
behind the observed association of statins and reduced
growth of AAA.
Our results are in line with the first two studies that
showed a slowing influence of statins on AAA expansion
rates. Schouten et al showed, comparable to our result, a
.3
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rate in users of statins compared with nonusers.3 Sukhija
et al2 reported that the sizes of AAAs of patients not treated
Table III. Estimated differences in mean annual AAA gro
Ad
diffe
Age (per y increase)
Female gender
AAA diameter at first screening (per mm increase)
Cerebral vascular disease
Myocardial infarction
Peripheral vascular disease
Mean systolic blood pressure (per mm Hg increase)
Mean diastolic blood pressure (per mm Hg increase)
Antihypertensive treatment
Hypertension  160/95 mm Hg
Hypertension  140/80 mm Hg
Diabetes mellitus
Weight (per kg increase)
Length (per dm increase)
Body mass index (per kg/m2 increase)
Waist to hip ratio (per unit increase)
Mean abdominal fat (per cm increase)
Lower resting ankle brachial index ( 0.90)
Mean intima media thickness (per mm)
Carotid stenosis  70% (duplex)
Hyperlipidemia
Lipid-lowering drug use
Triglycerides (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
Blood creatinine (mg/dl)
Renal failure
Assessment of creatinine clearance (Cockcroft)
Hyperhomocysteinemia
Smoking
HDL, High-density lipoprotein; LDL, low-density lipoprotein.
Table IV. Adjusted estimated difference in mean annual
AAA growth
Adjusted
estimated
difference
(mm/y)
95% confidence
interval
P value
Lower
bound
Upper
bound
Age (per y) .02 .07 .11 .700
Female gender .45 1.5 2.4 .655
AAA diameter at first
screening (per mm)
.09 .01 .18 .029
Length (per dm) .51 1.5 .50 .318
Weight (per kg) .02 .04 .07 .519
Diabetes mellitus .91 2.2 .36 .158
Cerebral vascular disease .70 2.1 .68 .315
Hypertension .88 .25 2.0 .124
Assessment of creatinine
clearance (Cockcroft)
.22 1.3 .82 .677
Hyperlipidemia .78 2.0 .45 .210
Lipid-lowering drug use 1.2 2.3 .06 .039a
AAA, Abdominal aortic aneurysms.
aP value  .05with statins significantly increased after 2 years of follow-up, but the sizes of AAAs did not significantly change in
patients treated with statins for the same period of
follow-up.
From the total study population, 79 AAAs (34%) were
not detected before the patient participated in the vascular
screening program. Implementation of a screening pro-
gram like the SMART study can considerably increase the
number of early detected AAAs. We found a low rupture
risk of 0.9% per patient-year for AAAs between 30 and 55
mated
(mm/y)
95% confidence interval
P valueLower bound Upper bound
7 .00 .13 .056
.58 2.8 .199
7 .01 .15 .073
2.4 .06 .062
0 1.7 .69 .410
5 .78 2.1 .373
1 .03 .05 .616
4 .03 .12 .237
0 .46 1.7 .263
9 .18 2.0 .104
3 1.3 1.7 .770
2.4 .04 .057
3 .07 .01 .131
5 1.2 .10 .099
6 .20 .09 .432
12 7.3 .649
6 .25 .36 .708
6 1.2 1.1 .912
5 1.4 .91 .670
1 1.8 .81 .445
3 1.5 .81 .573
2.2 .19 .021
0 .01 .01 .706
1 .06 .03 .565
0 .02 .02 .983
6 .39 .51 .792
3 1.0 1.5 .710
3 1.6 .10 .083
4 1.3 1.4 .947
0 .34 .95 .351
Fig 2. Cumulative long-term survival plot.wth
j. esti
rence
.0
1.1
.0
1.2
.5
.6
.0
.0
.6
.8
.2
1.2
.0
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.0
.2
.5
.3
1.2
.0
.0
.0
.0
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.7
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JOURNAL OF VASCULAR SURGERY
June 20081132 Schlösser et alDetection and Management Veterans Affairs Cooperative
Study Group have shown that early elective surgery for
small AAA (40 to 55mm) does not improve survival com-
pared with ultrasound surveillance, despite low operative
mortality.29-30 Lederle et al found a risk of 0.6% per year for
patients with AAAs between 40 and 55 mm.30 This low
rupture risk, added to the trial data, pleads for watchful
waiting rather than surgical exclusion of small AAA. Brady
et al suggested that screening intervals of 36, 24, 12, and 3
months for patients with AAA diameter 35, 40, 45, and 50
mm, respectively, yield less than a 1% chance of exceeding
55 mm at the subsequent screening.31
This study has some limitations. Interobserver variation
in ultrasound measurements has been described to be  2
mm in 95% of the cases.32-33 The calculated expansion rates
of patients in this study might therefore not correspond
with the real expansion rate in all patients. However, by
including all recorded AAA measurements in the linear
regression analysis (instead of only the first and last exami-
nations), the effect of variability in diameter measurements
have been reduced. Statin use was slightly less common in
the first 20% of included patients (statin use 25% to 30%),
but thereafter a constant proportion of 45% to 50% used
statins. We believe that this did not affect our results
importantly; however, we may underestimate the effect of
statins slightly compared with the current population with
more frequent use of statins and with longer duration.
Finally, patients enrolled in this study were not randomized
for lipid-lowering drug treatment. Comparison of baseline
characteristics between patients with and without lipid-
lowering drugs revealed that five variables significantly dif-
fered between users and nonusers: age, initial AAA diame-
ter, history of cardiac disease, hyperlipidemia, and intima
media thickness (IMT). AAA expansion rates were already
adjusted for age, initial AAA diameter, and hyperlipidemia
Table V. Causes of death of the patients in this cohort
All patients
(n  230)
Patients
selected for
AAA growth
rate analysis
(n  147)
n % n %
Fatal myocardial infarction 3 3.9 1 2.9
Fatal cerebral infarction 4 5.2 1 2.9
Fatal cerebral hemorrhage 1 1.3 0 0.0
Definite sudden death 3 3.9 2 5.9
Probable sudden death 12 16 5 14.7
Congestive heart failure 4 5.2 1 2.9
Fatal AAA rupture 6 7.8 5 14.7
Other vascular death 22 29 10 29.4
Fatal infection 2 2.6 1 2.9
Fatal malignancy 16 21 7 20.6
Unnatural death 1 1.3 0 0.0
Other nonvascular death 3 3.9 1 2.9
Total 77 100 34 100
AAA, Abdominal aortic aneurysms.in the multivariate linear regression model. The two othersignificantly different factors (“IMT” and “history of car-
diac disease”) were apparently not associated with AAA
expansion rates and therefore not incorporated in the mul-
tivariate model. Other variables did not significantly differ
between users and nonusers of lipid-lowering drugs. Al-
though we adjusted for several possibly confounding fac-
tors in the multivariate linear regression analysis, we could
not adjust for possible other, unknown confounders.
Given the inherent limitations of observational cohort
studies, the apparent slowing effect of statins on AAA
growth rate needs ideally confirmation by a randomized
placebo-controlled trial. However, as the majority of the
patients with an AAA are nowadays treated with statins, this
would hardly be possible in a placebo-controlled design.
CONCLUSIONS
Statins appear to be associated with lower AAA growth
rates. Higher initial diameters are associated with higher
growth rates. Other potential factors were not associated
with a significant difference in aneurysm growth rate. The
rupture risk of small abdominal aortic aneurysms is very
small, which pleads for watchful waiting.
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